P
petersymons
Guest
Just wondering if anyone here is involved in the combined VX770/809 trials?
regards Peter
regards Peter
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
P
petersymons
Guest
Just wondering if anyone here is involved in the combined VX770/809 trials?
regards Peter
regards Peter
P
petersymons
Guest
Just wondering if anyone here is involved in the combined VX770/809 trials?
<br />regards Peter
<br />regards Peter
LiveStrong
New member
Hey Peter,
not sure about the 770/809 trials but seems like vertex will be filing for VX-770 approval this year.
"We are in a unique position, as just behind telaprevir is VX-770, a medicine in development that aims to treat the underlying cause of cystic fibrosis. We will soon obtain data from the Phase 3 registration program of VX-770 that may support the planned submission of a New Drug Application to the FDA in the second half of this year."
<a target=_blank class=ftalternatingbarlinklarge href="http://finance.yahoo.com/news/Vertex-Announces-Key-Business-bw-4211373110.html?x=0&.v=1">http://finance.yahoo.com/news/...11373110.html?x=0&.v=1</a>
not sure about the 770/809 trials but seems like vertex will be filing for VX-770 approval this year.
"We are in a unique position, as just behind telaprevir is VX-770, a medicine in development that aims to treat the underlying cause of cystic fibrosis. We will soon obtain data from the Phase 3 registration program of VX-770 that may support the planned submission of a New Drug Application to the FDA in the second half of this year."
<a target=_blank class=ftalternatingbarlinklarge href="http://finance.yahoo.com/news/Vertex-Announces-Key-Business-bw-4211373110.html?x=0&.v=1">http://finance.yahoo.com/news/...11373110.html?x=0&.v=1</a>
LiveStrong
New member
Hey Peter,
not sure about the 770/809 trials but seems like vertex will be filing for VX-770 approval this year.
"We are in a unique position, as just behind telaprevir is VX-770, a medicine in development that aims to treat the underlying cause of cystic fibrosis. We will soon obtain data from the Phase 3 registration program of VX-770 that may support the planned submission of a New Drug Application to the FDA in the second half of this year."
<a target=_blank class=ftalternatingbarlinklarge href="http://finance.yahoo.com/news/Vertex-Announces-Key-Business-bw-4211373110.html?x=0&.v=1">http://finance.yahoo.com/news/...11373110.html?x=0&.v=1</a>
not sure about the 770/809 trials but seems like vertex will be filing for VX-770 approval this year.
"We are in a unique position, as just behind telaprevir is VX-770, a medicine in development that aims to treat the underlying cause of cystic fibrosis. We will soon obtain data from the Phase 3 registration program of VX-770 that may support the planned submission of a New Drug Application to the FDA in the second half of this year."
<a target=_blank class=ftalternatingbarlinklarge href="http://finance.yahoo.com/news/Vertex-Announces-Key-Business-bw-4211373110.html?x=0&.v=1">http://finance.yahoo.com/news/...11373110.html?x=0&.v=1</a>
LiveStrong
New member
Hey Peter,
<br />
<br />not sure about the 770/809 trials but seems like vertex will be filing for VX-770 approval this year.
<br />
<br />"We are in a unique position, as just behind telaprevir is VX-770, a medicine in development that aims to treat the underlying cause of cystic fibrosis. We will soon obtain data from the Phase 3 registration program of VX-770 that may support the planned submission of a New Drug Application to the FDA in the second half of this year."
<br />
<br /><a target=_blank class=ftalternatingbarlinklarge href="http://finance.yahoo.com/news/Vertex-Announces-Key-Business-bw-4211373110.html?x=0&.v=1">http://finance.yahoo.com/news/...11373110.html?x=0&.v=1</a>
<br />
<br />not sure about the 770/809 trials but seems like vertex will be filing for VX-770 approval this year.
<br />
<br />"We are in a unique position, as just behind telaprevir is VX-770, a medicine in development that aims to treat the underlying cause of cystic fibrosis. We will soon obtain data from the Phase 3 registration program of VX-770 that may support the planned submission of a New Drug Application to the FDA in the second half of this year."
<br />
<br /><a target=_blank class=ftalternatingbarlinklarge href="http://finance.yahoo.com/news/Vertex-Announces-Key-Business-bw-4211373110.html?x=0&.v=1">http://finance.yahoo.com/news/...11373110.html?x=0&.v=1</a>